Digest Network Come funziona
Network
/
Società
Ab
Non verificato

AbCellera Biologics Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

57 comunicati stampa

Guarda tutti i comunicati
22/10/2026
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Eventi
Web e Social Network
AbCellera to Present at Upcoming Investor Conferences in November 2026
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Eventi
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
01/10/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
16/09/2026
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
02/09/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
13/08/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
11/08/2026
Mercato azionario
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
10/08/2026
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
07/08/2026
Web e Social Network
Telefonia e Varie
Industria
Eventi
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0
05/08/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Oncologia
Salute
Vetrine/Shopping
Medicina - Varie
Farmaceutica
Biotecnologia
AbCellera Reports Q2 2026 Business Results
Fonte
AbCellera Biologics Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0